Sakuma, Noriko
Abe, Mitsuhiro
Ishii, Daisuke
Kawasaki, Takeshi
Arakawa, Noriaki
Matsuyama, Shinichiro
Saito, Yoshiro
Suzuki, Takuji
Tatsumi, Koichiro
Funding for this research was provided by:
the Japan Agency for Medical Research and Developmen (24mk0121256h0502, 24mk0121256h0502, 24mk0121256h0502, 24mk0121256h0502, 24mk0121256h0502, 24mk0121256h0502)
AMED (243fa627003h0003, 243fa627003h0003, 243fa627003h0003, 243fa627003h0003, 243fa627003h0003, 243fa627003h0003)
the Intractable Respiratory Diseases and Pulmonary Hypertension Research Group, Ministry of Health, Labor and Welfare, Japan (20FC1027, 20FC1027, 20FC1027, 20FC1027, 20FC1027, 20FC1027)
Article History
Received: 15 January 2024
Accepted: 24 July 2024
First Online: 29 July 2024
Declarations
:
: The clinical trial research protocol was approved by the Human Ethics Committee of Chiba University Hospital (approval number: 2083 and 2265) and complied with the Declaration of Helsinki Ethical Principles for medical research involving human subjects. We obtained written informed consent from all the patients.
: Not applicable.
: The authors declare no competing interests. NA and YS are inventors of patents related to stratifin involved in the diagnosis of ILD as filed by the National Institute of Health Science.